SGR-1505 was observed to have a favorable safety profile and was well tolerated, with encouraging preliminary efficacy in patients with relapsed/refractory B-cell malignancies Responses observed ...

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. has launched a Phase 1 clinical study titled A Phase 1, Randomized, Multi-Center, Double-Blind, Sponsor Open, ...

Almirall SA (GB:0O9B) announced an update on their ongoing clinical study. Almirall SA has recently completed a Phase 1 clinical study titled A Phase 1 Randomized, 3-Part, Placebo-Controlled, Single ...

BioAtla, Inc. has announced promising preliminary results from a Phase 1 clinical trial of BA3182, a dual-Conditionally Active Biologic bispecific T-cell engager targeting EpCAM and CD3, for treating ...

MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated clinical ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive ...

Analysis of the final APEX Phase 1b clinical results obtained with KSI-101 (Kodiak Sciences Inc.) evaluated to treat macular edema secondary to inflammation (MESI) showed that at week 24 well over ...

Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...

Monte Rosa Therapeutics, Inc. has initiated a Phase 1 study for MRT-8102, a novel molecular glue degrader targeting the NEK7 protein to treat inflammatory conditions linked to the NLRP3 inflammasome.

CheMo4METPANC: Combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic ...